Single Agent Therapy
Phase 1
Single Agent Therapy is one of 40 therapeutic programs targeting Glioma. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
394 competitors in Glioma
#DrugCompanyPhaseTrials
1Paraplatin
AAvyxa
Phase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Vepesid
AAvyxa
Phase 3
Photofrin
PPinnacle Biologics Inc.
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Velban
EEastern Cooperative Oncology Group
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Modeyso
CChimerix
Phase 3
Selumetinib /m2
NNational Cancer Institute (NCI)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Single Agent Therapy. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- TTheodore Brasky PhD